H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Cardiff Oncology to $12 from $13 and keeps a Buy rating on the shares post the Q2 report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CRDF:
- Cardiff Oncology reports Q2 EPS (25c), consensus (26c)
- Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update
- Cardiff Oncology (NASDAQ:CRDF) Rockets Upward With New Support, Cancer Treatments
- Cardiff Oncology price target lowered to $13 from $14 at H.C. Wainwright
- Cardiff Oncology to conduct new CRDF-004 trial with support from Pfizer Ignite
